Clinical trials: Alcohol Dependence, in Remission
Opioid-use Disorder, Opioid Abuse, in Remission
Mindfulness-Based Relapse Prevention for Opioid and Alcohol Use Disorders
A randomized controlled trial will examine mindfulness-based relapse prevention (MBRP) program outcomes for 240 individuals who have completed treatment for opioid or alcohol use disorders.
- Conditions
- Opioid-use Disorder, Opioid Abuse, in Remission, Alcohol Use Disorder, Alcohol Use Disorder, in Remission
- Trial name
- MBRP (NCT04278352)
- Testing
- Mindfulness Based Relapse Prevention
- Where
- 3 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Clemson University
Alcohol Use Disorder, Alcohol Use, Unspecified
Drinking, Acetate, and Stress
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry.
- Conditions
- Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
- Trial name
- NCT06584448
- Testing
- Deuterium Metabolic Imaging with deuterated acetate tracer
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci